Early Data Suggest Novo Nordisk's Long-Acting Insulin Degludec On Par With Sanofi's Lantus
This article was originally published in The Pink Sheet Daily
Executive Summary
Much anticipated Phase II data suggest Degludec is as good as Lantus, but unseating the market leader will require showing superiority in either maintaining blood glucose control or incidence of hypoglycemia.
You may also be interested in...
Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.
Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.
Novo Nordisk's GLP-1 Victoza Off To A Good Start
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.